{"success":true,"data":{"pressRelease":{"id":"94234","rtpr_id":"nBw7G1cf3a","ticker":"EUFI","exchange":"Euronext Paris","all_tickers":["EUFI"],"title":"Eurofins Scientific: Director/PDMR Shareholding","author":"Business Wire","published_at":"2026-07-21T15:41:00.074Z","article_body":"Eurofins Scientific: Director/PDMR Shareholding\n\nEurofins Scientific SE (EUFI.PA) (Paris:ERF) has received various\nnotifications of dealing from Persons Discharging Managerial Responsibilities\n(“PDMR”). The notification of Dealing Form for each PDMR can be found\nbelow.\n\nThis notification is made in accordance with the European Market Abuse\nRegulation.\n NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING \n MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM \n     \n 1. Details of the person discharging managerial responsibilities/person closely \n associated \n a) Name Analytical Bioventures S.C.A (RCS B89265) \n \n23, Val Fleuri, L-1526 Luxembourg \n   \n 2. Reason for the notification \n a) Position / status Analytical Bioventures S.C.A. is a company controlled by Eurofins Scientific \n S.E., CEO Dr. Gilles Martin \n b) Initial notification / amendment Initial \n   \n 3. Details of the issuer, emission allowance market participant, auction \n platform, auctioneer or auction monitor \n a) Name Eurofins Scientific S.E.   \n b) LEI 529900JEHFM47DYY3S57   \n   \n 4. Details of the transaction(s) section to be repeated for (i) each type of \n instrument; (ii) each type of transaction; (iii) each date; and (iv) each \n place where transactions have been conducted \n a) Description of the financial instrument, type of instrument Share \n   Identification code ISIN: FR0014000MR3 \n b) Nature of the transaction Acquisition of shares   \n   \n c) Price(s) and volume(s) Price(s) Volume(s) \n EUR 68.9817 1,000 \n d) Aggregated information   \n — Aggregated volume 1,000   \n — Price EUR 68,981.70 \n e) Date of the transaction 2026-07-16 \n f) Place of the transaction XPAR \n\n NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING \n MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM \n     \n 1. Details of the person discharging managerial responsibilities/person closely \n associated \n a) Name Analytical Bioventures S.C.A (RCS B89265) \n \n23, Val Fleuri, L-1526 Luxembourg \n   \n 2. Reason for the notification \n a) Position / status Analytical Bioventures S.C.A. is a company controlled by Eurofins Scientific \n S.E., CEO Dr. Gilles Martin \n b) Initial notification / amendment Initial \n   \n 3. Details of the issuer, emission allowance market participant, auction \n platform, auctioneer or auction monitor \n a) Name Eurofins Scientific S.E.   \n b) LEI 529900JEHFM47DYY3S57   \n     \n 4. Details of the transaction(s) section to be repeated for (i) each type of \n instrument; (ii) each type of transaction; (iii) each date; and (iv) each \n place where transactions have been conducted \n a) Description of the financial instrument, type of instrument Share \n   Identification code ISIN: FR0014000MR3 \n b) Nature of the transaction Acquisition of shares   \n   \n c) Price(s) and volume(s) Price(s) Volume(s) \n EUR 70.00 9 \n d) Aggregated information   \n — Aggregated volume 9   \n — Price EUR 630.00 \n e) Date of the transaction 2026-07-17 \n f) Place of the transaction XPAR \n\n\nAbout Eurofins – the global leader in bio-analysis\n\nEurofins is Testing for Life. With over 65,000 staff across a network of more\nthan 950 laboratories in over 1,000 companies in 59 countries, Eurofins offers\na portfolio of over 200,000 analytical methods.\n\nEurofins Scientific S.E. shares are listed on Euronext Paris Stock Exchange.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260721150958/en/\n(https://www.businesswire.com/news/home/20260721150958/en/)\n\nFor more information, please visit www.eurofins.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.eurofins.com%2F&esheet=54574426&newsitemid=20260721150958&lan=en-US&anchor=www.eurofins.com&index=1&md5=567dd38e40fb8d2f7d5b0e0914c1f95c)\nor contact:\n\n\n\nInvestor Relations\n\nEurofins Scientific SE\n\nPhone: +32 2 766 1620\n\nE-mail: ir@sc.eurofinseu.com (mailto:ir@sc.eurofinseu.com)\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw7G1cf3a","title":"Eurofins Scientific: Director/PDMR Shareholding","author":"Business Wire","ticker":"EUFI","created":"2026-07-21T15:41:00.074Z","tickers":["EUFI"],"exchange":"Euronext Paris","article_body":"Eurofins Scientific: Director/PDMR Shareholding\n\nEurofins Scientific SE (EUFI.PA) (Paris:ERF) has received various\nnotifications of dealing from Persons Discharging Managerial Responsibilities\n(“PDMR”). The notification of Dealing Form for each PDMR can be found\nbelow.\n\nThis notification is made in accordance with the European Market Abuse\nRegulation.\n NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING \n MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM \n     \n 1. Details of the person discharging managerial responsibilities/person closely \n associated \n a) Name Analytical Bioventures S.C.A (RCS B89265) \n \n23, Val Fleuri, L-1526 Luxembourg \n   \n 2. Reason for the notification \n a) Position / status Analytical Bioventures S.C.A. is a company controlled by Eurofins Scientific \n S.E., CEO Dr. Gilles Martin \n b) Initial notification / amendment Initial \n   \n 3. Details of the issuer, emission allowance market participant, auction \n platform, auctioneer or auction monitor \n a) Name Eurofins Scientific S.E.   \n b) LEI 529900JEHFM47DYY3S57   \n   \n 4. Details of the transaction(s) section to be repeated for (i) each type of \n instrument; (ii) each type of transaction; (iii) each date; and (iv) each \n place where transactions have been conducted \n a) Description of the financial instrument, type of instrument Share \n   Identification code ISIN: FR0014000MR3 \n b) Nature of the transaction Acquisition of shares   \n   \n c) Price(s) and volume(s) Price(s) Volume(s) \n EUR 68.9817 1,000 \n d) Aggregated information   \n — Aggregated volume 1,000   \n — Price EUR 68,981.70 \n e) Date of the transaction 2026-07-16 \n f) Place of the transaction XPAR \n\n NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING \n MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM \n     \n 1. Details of the person discharging managerial responsibilities/person closely \n associated \n a) Name Analytical Bioventures S.C.A (RCS B89265) \n \n23, Val Fleuri, L-1526 Luxembourg \n   \n 2. Reason for the notification \n a) Position / status Analytical Bioventures S.C.A. is a company controlled by Eurofins Scientific \n S.E., CEO Dr. Gilles Martin \n b) Initial notification / amendment Initial \n   \n 3. Details of the issuer, emission allowance market participant, auction \n platform, auctioneer or auction monitor \n a) Name Eurofins Scientific S.E.   \n b) LEI 529900JEHFM47DYY3S57   \n     \n 4. Details of the transaction(s) section to be repeated for (i) each type of \n instrument; (ii) each type of transaction; (iii) each date; and (iv) each \n place where transactions have been conducted \n a) Description of the financial instrument, type of instrument Share \n   Identification code ISIN: FR0014000MR3 \n b) Nature of the transaction Acquisition of shares   \n   \n c) Price(s) and volume(s) Price(s) Volume(s) \n EUR 70.00 9 \n d) Aggregated information   \n — Aggregated volume 9   \n — Price EUR 630.00 \n e) Date of the transaction 2026-07-17 \n f) Place of the transaction XPAR \n\n\nAbout Eurofins – the global leader in bio-analysis\n\nEurofins is Testing for Life. With over 65,000 staff across a network of more\nthan 950 laboratories in over 1,000 companies in 59 countries, Eurofins offers\na portfolio of over 200,000 analytical methods.\n\nEurofins Scientific S.E. shares are listed on Euronext Paris Stock Exchange.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260721150958/en/\n(https://www.businesswire.com/news/home/20260721150958/en/)\n\nFor more information, please visit www.eurofins.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.eurofins.com%2F&esheet=54574426&newsitemid=20260721150958&lan=en-US&anchor=www.eurofins.com&index=1&md5=567dd38e40fb8d2f7d5b0e0914c1f95c)\nor contact:\n\n\n\nInvestor Relations\n\nEurofins Scientific SE\n\nPhone: +32 2 766 1620\n\nE-mail: ir@sc.eurofinseu.com (mailto:ir@sc.eurofinseu.com)\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-07-21T15:41:00.128798244Z","server_sent_at_ms":1784648460128},"received_at":"2026-07-21T15:41:00.223Z","source_url":"https://www.businesswire.com/news/home/20260721150958/en/"},"analysis":{"id":"83271","press_release_id":"94234","analysis_json":{"industry":{"label":"Life Sciences Tools & Services","sector":"Health Care"},"redFlags":[],"eventType":"insider_transaction","narrative":"Eurofins Scientific disclosed that Analytical Bioventures S.C.A., a company controlled by CEO Dr. Gilles Martin, acquired shares in the open market.\n\nThe entity purchased 1,000 shares on July 16 at a price of EUR 68.9817 per share and 9 shares on July 17 at EUR 70.00 per share.\n\nThe transactions, totaling approximately EUR 69,612, were reported in accordance with European Market Abuse Regulation requirements.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"CEO-controlled entity adds to position in minor open-market buys."},"keyFigures":{"customDimensions":{"transaction_1_date":"2026-07-16","transaction_2_date":"2026-07-17","transaction_1_shares":1000,"transaction_2_shares":9,"transaction_1_price_eur":68.9817,"transaction_1_total_eur":68981.7,"transaction_2_price_eur":70,"transaction_2_total_eur":630}},"quotedText":"","namedEntities":{"people":[{"name":"Dr. Gilles Martin","role":"CEO"}],"products":[],"companies":[{"name":"Eurofins Scientific SE","ticker":"EUFI.PA"},{"name":"Analytical Bioventures S.C.A","relationship":"PDMR / Controlled by CEO"}],"dollarAmounts":[{"amount":"EUR 68,981.70","context":"Total consideration for 1,000 shares acquired on July 16"},{"amount":"EUR 630.00","context":"Total consideration for 9 shares acquired on July 17"}]},"materialImpact":{"score":2,"reasoning":"The disclosure details small open market purchases by a company controlled by the CEO. While insider buying is a positive signal of confidence, the volume (approx. EUR 70k) is financially immaterial relative to the company's market cap."},"tickerRelevance":{"others":[],"primary":"EUFI"},"globalImportance":10,"audienceRelevance":30,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"large-cap","eventGravity":"routine-insider-buy","transactionValue":"low"}},"event_type":"insider_transaction","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"Eurofins Scientific disclosed that Analytical Bioventures S.C.A., a company controlled by CEO Dr. Gilles Martin, acquired shares in the open market.\n\nThe entity purchased 1,000 shares on July 16 at a price of EUR 68.9817 per share and 9 shares on July 17 at EUR 70.00 per share.\n\nThe transactions, totaling approximately EUR 69,612, were reported in accordance with European Market Abuse Regulation requirements.","key_figures":{"customDimensions":{"transaction_1_date":"2026-07-16","transaction_2_date":"2026-07-17","transaction_1_shares":1000,"transaction_2_shares":9,"transaction_1_price_eur":68.9817,"transaction_1_total_eur":68981.7,"transaction_2_price_eur":70,"transaction_2_total_eur":630}},"named_entities":{"people":[{"name":"Dr. Gilles Martin","role":"CEO"}],"products":[],"companies":[{"name":"Eurofins Scientific SE","ticker":"EUFI.PA"},{"name":"Analytical Bioventures S.C.A","relationship":"PDMR / Controlled by CEO"}],"dollarAmounts":[{"amount":"EUR 68,981.70","context":"Total consideration for 1,000 shares acquired on July 16"},{"amount":"EUR 630.00","context":"Total consideration for 9 shares acquired on July 17"}]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-07-21T19:03:47.260Z","global_importance":10,"audience_relevance":30,"importance_components":{"tickerTier":"large-cap","eventGravity":"routine-insider-buy","transactionValue":"low"}},"durationMs":51069,"modelName":"glm-4.7"}}